Lauritsen Bullard (rubring10)

NRC Report PIRS-0626 (https//doi.org/10.4224/40000364) describes how measured electron energy deposition spectra can be used to determine the electronic stopping power. The stopping power is obtained by comparing measured spectra with spectra calculated using Monte Carlo techniques. The stopping powers reported in PIRS-0626 were obtained using the EGS4 Monte Carlo code. Since then, the EGSnrc code has been released which has more accurate electron transport algorithms. We calculate the effect on the measured stopping powers of using EGSnrc instead of EGS4. The EGS4 spectra calculated in PIRS-0626 were based on 4 × 10 5 primary electron histories. We first show that those spectra, calculated in 1997, are consistent with current EGS4 spectra calculated using 10 8 histories. EGSnrc spectra are also calculated using 10 8 histories and theseW air , using aluminum detectors will provide an interesting test of the aluminum stopping power data as reported in PIRS-0626 and revised by this work. The differences introduced by using EGSnrc instead of EGS4 can affect the estimated stopping power by almost 1% in the worst case but generally the effect is much smaller. We report corrections that can be applied to all the stopping power data in PIRS-0626. An experiment to measure the average energy to create an ion pair in air, W air , using aluminum detectors will provide an interesting test of the aluminum stopping power data as reported in PIRS-0626 and revised by this work. Newly diagnosed advanced-stage ovarian cancer patients are treated with neoadjuvant chemotherapy, primary or intermediate cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy (HIPEC). The aim of this study is to evaluate the optimal timing of cytoreduction plus HIPEC for advanced ovarian cancer patients. Advanced ovarian cancer patients treated with cytoreductive surgery plus HIPEC at three different hospitals between 2005 and 2019 were subgrouped regarding their time of management with cytoreduction plus HIPEC, upfront or intermediate. read more We retrospectively assessed the overall survival (OS), the progression-free survival (PFS), and the disease-free survival (DFS) of these groups. A total of 112 ovarian cancer patients were contained. Of whom, 47 patients were in the upfront group with 24 (51.1%) to be alive, while 65 patients were included in the intermediate group with 34 (52.3%) to be alive. OS (48 vs. 30 months) and DFS (42 vs. 20 months) indicated no significant difference. Although the same median PFS was observed in both groups (10 months), a higher mean PFS was observed in the upfront group (11.9 vs. 9 months, p = 0.023). The treatment of advanced ovarian cancer patients with upfront cytoreductive surgery plus HIPEC is feasible with the same survival results. Further, larger prospective studies need to verify our results. The treatment of advanced ovarian cancer patients with upfront cytoreductive surgery plus HIPEC is feasible with the same survival results. Further, larger prospective studies need to verify our results. Pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare subtype of primary lung cancer. The present study aims at investigating clinicopathological features and prognostic characteristics of the resected pulmonary LELC. Patients with resected pulmonary LELC were identified in our hospital from December 2008 to December 2018. Data of these patients were retrospectively reviewed, clinicopathological features and prognostic characteristics were analyzed subsequently. In total, 86 patients were enrolled in the study,